NCT05579249CompletedPhase 4
A Research Study Comparing Wegovy to Other Weight Management Drugs in People Living With Obesity in America
Effectiveness of Semaglutide 2.4 mg vs. Commercially Available Medications for Chronic Weight Management in Participants With Obesity in a Multi-employer Setting in The US - a Pragmatic Clinical Study
Source: ClinicalTrials.gov · Last updated 14 Jan 2026
Brief summary (registry, in English)
The purpose of this post approval pragmatic clinical study is to see how well semaglutide lowers body weight compared to other medication on the market used to treat obesity, across three US-based employers. These employers represent employees of diverse demography and job functions including hospitality, clerical, administrative, housekeeping, maintenance, and specialised employees across a range of socioeconomic and educational backgrounds. The study will also look at how weight loss affects physical functioning, quality of life and ability to work. It will also gather information on how satisfied participants are with the medication they take. Participants will either receive semaglutide or one of 4 approved anti-obesity medication (Xenical/Qsymia/Contrave/Saxenda).
- Status (registry)
- Completed
- Phase (registry)
- Phase 4
- Study type
- Interventional
- Enrollment
- 500 (actual)
- First submitted
- 11 Oct 2022
- Start date
- 19 Jan 2023
- Primary completion date
- 27 Nov 2024
- Lead sponsor
- Novo Nordisk A/S
- Diseases
- Obesity
- NCT number
- NCT05579249
What you commit to
- Study type: Interventional · Phase 4
- Participants enrolled: 500
- From 19 Jan 2023 to the primary completion date, 27 Nov 2024
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Known or suspected hypersensitivity or contraindications to Wegovy or related products according to the label.
- Known or suspected hypersensitivity or contraindications to all of the other Anti-Obesity Medications (AOMs) for chronic weight management (Xenical, Qsymia, Contrave, and Saxenda) or related products according to the labels.
- History of type 1 or type 2 diabetes mellitus.
- Any disorder, unwillingness, or inability, not covered by any of the other exclusion criteria, which in the investigator's opinion might jeopardise participant's safety or compliance with protocol.
Other
- Female who is pregnant, breast-feeding or intends to become pregnant or is of childbearing potential and not using highly effective contraceptive method.
Who the study is looking for
- Body mass index (BMI) greater than equal to 30.0 kilogram per meter square (kg/m\^2).
- Employed at randomisation by one of the selected employers and expecting to be so for the duration of the study.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Nutrition Research Centre Coordinator of this site? Confirm its status | Loma Linda | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.